Martina Ceckova

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8587310/publications.pdf

Version: 2024-02-01

52 papers	2,216 citations	218677 26 h-index	223800 46 g-index
52 all docs	52 docs citations	52 times ranked	2533 citing authors

#	Article	IF	Citations
1	Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicology and Applied Pharmacology, 2022, 434, 115797.	2.8	4
2	ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia. Biomedicine and Pharmacotherapy, 2022, 150, 112962.	5.6	4
3	Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta. Biomedicine and Pharmacotherapy, 2020, 129, 110506.	5.6	6
4	In vitro function and in situ localization of Multidrug Resistance-associated Protein (MRP)1 (ABCC1) suggest a protective role against methyl mercury-induced oxidative stress in the human placenta. Archives of Toxicology, 2020, 94, 3799-3817.	4.2	14
5	Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. Cancers, 2020, 12, 1596.	3.7	13
6	Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics. Drug Metabolism and Disposition, 2019, 47, 954-960.	3.3	13
7	Brivanib Exhibits Potential for Pharmacokinetic Drugâ€“Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Molecular Pharmaceutics, 2019, 16, 4436-4450.	4.6	22
8	Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters. Biochemical Pharmacology, 2019, 163, 60-70.	4.4	11
9	Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metabolism and Disposition, 2019, 47, 699-709.	3.3	15
10	Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochemical Pharmacology, 2019, 163, 290-298.	4.4	9
11	The inhibitory effect of antiretroviral drugs on the L-carnitine uptake in human placenta. Toxicology and Applied Pharmacology, 2019, 368, 18-25.	2.8	10
12	Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochemical Pharmacology, 2018, 154, 10-17.	4.4	41
13	LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1089, 24-32.	2.3	0
14	Equilibrative Nucleoside Transporter 1 (ENT1, SLC29A1) Facilitates Transfer of the Antiretroviral Drug Abacavir across the Placenta. Drug Metabolism and Disposition, 2018, 46, 1817-1826.	3.3	25
15	Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate). PLoS ONE, 2018, 13, e0202706.	2.5	11
16	In vitro and in silico Evaluation of Non-Quaternary Reactivators of AChE as Antidotes of Organophosphorus Poisoning - a New Hope or a Blind Alley?. Medicinal Chemistry, 2018, 14, 281-292.	1.5	19
17	Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica, 2017, 47, 77-85.	1.1	27
18	Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV. Journal of Pharmaceutical and Biomedical Analysis, 2017, 137, 70-77.	2.8	1

#	Article	IF	Citations
19	Role of nucleoside transporters in transplacental pharmacokinetics of nucleoside reverse transcriptase inhibitors zidovudine and emtricitabine. Placenta, 2017, 60, 86-92.	1.5	12
20	MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	23
21	Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs). Xenobiotica, 2016, 46, 416-423.	1.1	1
22	Etravirine inhibits ABCG2 drug transporter and affects transplacental passage of tenofovir disoproxil fumarate. Placenta, 2016, 47, 124-129.	1.5	13
23	Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine. Antimicrobial Agents and Chemotherapy, 2016, 60, 5563-5572.	3.2	19
24	Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine. Biopharmaceutics and Drug Disposition, 2016, 37, 28-38.	1.9	24
25	Regulation of drug transporter expression and function in the placenta. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 533-555.	3.3	40
26	Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir. Reproductive Toxicology, 2015, 57, 176-182.	2.9	29
27	Boldine enhances bile production in rats via osmotic and Farnesoid X receptor dependent mechanisms. Toxicology and Applied Pharmacology, 2015, 285, 12-22.	2.8	19
28	Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cancer Chemotherapy and Pharmacology, 2015, 76, 105-116.	2.3	28
29	Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro. Biochemical Pharmacology, 2015, 98, 465-472.	4.4	27
30	Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. Aids, 2014, 28, 9-17.	2.2	68
31	Multidrug and toxin extrusion proteins (MATE/SLC47); role in pharmacokinetics. International Journal of Biochemistry and Cell Biology, 2013, 45, 2007-2011.	2.8	61
32	Tetratricopeptide Repeat Motifs in the World of Bacterial Pathogens: Role in Virulence Mechanisms. Infection and Immunity, 2013, 81, 629-635.	2.2	156
33	Organic Cation Transporter 3 (OCT3/SLC22A3) and Multidrug and Toxin Extrusion 1 (MATE1/SLC47A1) Transporter in the Placenta and Fetal Tissues: Expression Profile and Fetus Protective Role at Different Stages of Gestation1. Biology of Reproduction, 2013, 88, 55.	2.7	58
34	Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1). PLoS ONE, 2013, 8, e75520.	2.5	6
35	Purvalanol A, Olomoucine II and Roscovitine Inhibit ABCB1 Transporter and Synergistically Potentiate Cytotoxic Effects of Daunorubicin In Vitro. PLoS ONE, 2013, 8, e83467.	2.5	27
36	Synchronized Activity of Organic Cation Transporter 3 (Oct3/Slc22a3) and Multidrug and Toxin Extrusion 1 (Mate1/Slc47a1) Transporter in Transplacental Passage of MPP+ in Rat. Toxicological Sciences, 2012, 128, 471-481.	3.1	38

#	Article	IF	Citations
37	Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. Journal of Drug Targeting, 2012, 20, 736-763.	4.4	99
38	Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacological Research, 2012, 65, 312-319.	7.1	23
39	Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metabolism Reviews, 2011, 43, 53-68.	3.6	42
40	Expression and Function of P-Glycoprotein in Normal Tissues: Effect on Pharmacokinetics. Methods in Molecular Biology, 2010, 596, 199-222.	0.9	74
41	Transplacental Pharmacokinetics of Glyburide, Rhodamine 123, and BODIPY FL Prazosin: Effect of Drug Efflux Transporters and Lipid Solubility. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 1118-1125.	2.5	64
42	Variation of Drug Kinetics in Pregnancy. Current Drug Metabolism, 2009, 10, 520-529.	1.2	93
43	Role of breast cancer resistance protein (Bcrp/Abcg2) in fetal protection during gestation in rat. Toxicology Letters, 2008, 178, 176-180.	0.8	44
44	Effect of ABCG2 on cytotoxicity of platinum drugs: Interference of EGFP. Toxicology in Vitro, 2008, 22, 1846-1852.	2.4	28
45	Salicylanilide Acetates: Synthesis and Antibacterial Evaluation. Molecules, 2007, 12, 1-12.	3.8	40
46	EXPRESSION AND FUNCTIONAL ACTIVITY OF BREAST CANCER RESISTANCE PROTEIN (BCRP, ABCG2) TRANSPORTER IN THE HUMAN CHORIOCARCINOMA CELL LINE BEWO. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 58-65.	1.9	74
47	Synthesis and antimicrobial evaluation of new 2-substituted 5,7-di-tert-butylbenzoxazoles. Bioorganic and Medicinal Chemistry, 2006, 14, 5850-5865.	3.0	100
48	P-glycoprotein in the placenta: Expression, localization, regulation and function. Reproductive Toxicology, 2006, 22, 400-410.	2.9	187
49	Expression and Transport Activity of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Dually Perfused Rat Placenta and HRP-1 Cell Line. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 53-62.	2.5	79
50	Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 144-152.	2.5	258
51	P-glycoprotein expression and distribution in the rat placenta during pregnancy. Reproductive Toxicology, 2004, 18, 785-792.	2.9	63
52	Examination of the Functional Activity of P-glycoprotein in the Rat Placental Barrier Using Rhodamine 123. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 1239-1250.	2.5	54